Invitrogen’s patent applications which are part of this agreement cover stealth and other proprietary technologies related to enhanced configurations of chemically modified double-stranded RNA.
Dr Tod Woolf, president and CEO of RXi, said: “Licensing this broad technology from Invitrogen is part of our strategy to continually enhance our proprietary rxRNA compounds for therapeutic applications.”
Amy Butler, Invitrogen vice president of gene expression profiling, said: “Currently Invitrogen stealth RNAi synthetic duplexes are widely used for RNA interference (RNAi) research across both in vitro and in vivo applications due to their specificity, efficacy and stability. We see the use of our stealth RNAi technology in therapeutics as a natural next step in Invitrogen’s efforts to be at the cutting edge of in vivo gene regulation.”